
Sign up to save your podcasts
Or


The editors also review the evidence for cladribine for the treatment of highly active relapsing multiple sclerosis (http://dtb.bmj.com/content/56/2/21) and discuss the latest levonorgestrel IUS device to be marketed for contraception (http://dtb.bmj.com/content/56/2/18).
By BMJ Group4.8
44 ratings
The editors also review the evidence for cladribine for the treatment of highly active relapsing multiple sclerosis (http://dtb.bmj.com/content/56/2/21) and discuss the latest levonorgestrel IUS device to be marketed for contraception (http://dtb.bmj.com/content/56/2/18).

83 Listeners

2,083 Listeners

39 Listeners

51 Listeners

94 Listeners

8 Listeners

5 Listeners

3 Listeners

2 Listeners

4 Listeners

9 Listeners

38 Listeners

14 Listeners

1 Listeners

51 Listeners

0 Listeners

6 Listeners

14 Listeners

85 Listeners

3 Listeners

21 Listeners

3 Listeners

26 Listeners

24 Listeners

140 Listeners

50 Listeners

11 Listeners

9 Listeners

21 Listeners

5 Listeners

5 Listeners

97 Listeners